Synaptogenix (SNPX) Competitors $6.16 -0.43 (-6.53%) As of 09/11/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock SNPX vs. SNTI, RENB, RNTX, ITRM, KLTO, RVPH, KZR, CASI, DARE, and AKTXShould you be buying Synaptogenix stock or one of its competitors? The main competitors of Synaptogenix include Senti Biosciences (SNTI), Renovaro (RENB), Rein Therapeutics (RNTX), Iterum Therapeutics (ITRM), Klotho Neurosciences (KLTO), Reviva Pharmaceuticals (RVPH), Kezar Life Sciences (KZR), CASI Pharmaceuticals (CASI), Dare Bioscience (DARE), and Akari Therapeutics (AKTX). These companies are all part of the "pharmaceutical products" industry. Synaptogenix vs. Its Competitors Senti Biosciences Renovaro Rein Therapeutics Iterum Therapeutics Klotho Neurosciences Reviva Pharmaceuticals Kezar Life Sciences CASI Pharmaceuticals Dare Bioscience Akari Therapeutics Synaptogenix (NASDAQ:SNPX) and Senti Biosciences (NASDAQ:SNTI) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, risk, earnings, valuation, media sentiment and analyst recommendations. Is SNPX or SNTI more profitable? Synaptogenix's return on equity of -115.28% beat Senti Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets SynaptogenixN/A -115.28% -58.31% Senti Biosciences N/A -223.98%-76.02% Do analysts recommend SNPX or SNTI? Senti Biosciences has a consensus price target of $8.50, suggesting a potential upside of 529.63%. Given Senti Biosciences' stronger consensus rating and higher probable upside, analysts plainly believe Senti Biosciences is more favorable than Synaptogenix.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Synaptogenix 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Senti Biosciences 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media favor SNPX or SNTI? In the previous week, Senti Biosciences had 2 more articles in the media than Synaptogenix. MarketBeat recorded 2 mentions for Senti Biosciences and 0 mentions for Synaptogenix. Senti Biosciences' average media sentiment score of 1.45 beat Synaptogenix's score of 0.00 indicating that Senti Biosciences is being referred to more favorably in the news media. Company Overall Sentiment Synaptogenix Neutral Senti Biosciences Positive Which has higher earnings & valuation, SNPX or SNTI? Synaptogenix has higher earnings, but lower revenue than Senti Biosciences. Synaptogenix is trading at a lower price-to-earnings ratio than Senti Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSynaptogenixN/AN/A-$12.77M-$10.08-0.61Senti Biosciences$2.56M13.80-$52.79M-$8.95-0.15 Which has more risk and volatility, SNPX or SNTI? Synaptogenix has a beta of 1.08, indicating that its stock price is 8% more volatile than the S&P 500. Comparatively, Senti Biosciences has a beta of 2.06, indicating that its stock price is 106% more volatile than the S&P 500. Do institutionals & insiders hold more shares of SNPX or SNTI? 10.3% of Synaptogenix shares are held by institutional investors. Comparatively, 25.7% of Senti Biosciences shares are held by institutional investors. 2.7% of Synaptogenix shares are held by insiders. Comparatively, 3.1% of Senti Biosciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. SummarySenti Biosciences beats Synaptogenix on 11 of the 14 factors compared between the two stocks. Get Synaptogenix News Delivered to You Automatically Sign up to receive the latest news and ratings for SNPX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SNPX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SNPX vs. The Competition Export to ExcelMetricSynaptogenixMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$8.56M$3.20B$5.86B$10.15BDividend YieldN/A2.30%5.68%4.59%P/E Ratio-0.6121.1774.5225.93Price / SalesN/A473.02539.62123.65Price / CashN/A46.6837.5660.44Price / Book1.429.6112.166.29Net Income-$12.77M-$53.29M$3.28B$270.77M7 Day Performance6.39%0.29%0.98%3.36%1 Month Performance-16.64%8.91%7.20%6.41%1 Year Performance116.14%13.14%63.06%28.26% Synaptogenix Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SNPXSynaptogenixN/A$6.16-6.5%N/A+130.4%$8.56MN/A-0.614SNTISenti Biosciences3.2328 of 5 stars$1.30-1.5%$8.50+553.8%-54.6%$34.53M$2.56M-0.154Short Interest ↓RENBRenovaro0.8793 of 5 stars$0.22+18.2%N/A-69.3%$32.38MN/A-0.2920High Trading VolumeRNTXRein Therapeutics1.0008 of 5 stars$1.31-2.2%N/AN/A$31.23MN/A-0.499News CoverageITRMIterum Therapeutics2.8366 of 5 stars$0.70+6.2%$9.00+1,183.9%-32.8%$31.15MN/A-0.8210Positive NewsShort Interest ↓KLTOKlotho Neurosciences0.4472 of 5 stars$0.54+7.4%N/AN/A$30.75MN/A-1.20N/AGap UpRVPHReviva Pharmaceuticals2.9936 of 5 stars$0.450.0%$5.20+1,063.6%-65.9%$30.40MN/A-0.695KZRKezar Life Sciences3.8452 of 5 stars$4.02+0.2%$9.00+123.9%-31.1%$29.37MN/A-0.4160CASICASI Pharmaceuticals3.7617 of 5 stars$2.34-0.4%$4.00+70.9%-69.1%$28.90M$28.54M-0.81180Gap DownDAREDare Bioscience2.2946 of 5 stars$2.16+1.4%$10.00+363.0%-35.3%$28.71M$10K-1.0130Short Interest ↓AKTXAkari Therapeutics3.7267 of 5 stars$0.84-1.2%$3.30+292.8%-78.0%$27.72MN/A0.009Analyst ForecastShort Interest ↓ Related Companies and Tools Related Companies Senti Biosciences Alternatives Renovaro Alternatives Rein Therapeutics Alternatives Iterum Therapeutics Alternatives Klotho Neurosciences Alternatives Reviva Pharmaceuticals Alternatives Kezar Life Sciences Alternatives CASI Pharmaceuticals Alternatives Dare Bioscience Alternatives Akari Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SNPX) was last updated on 9/12/2025 by MarketBeat.com Staff From Our PartnersForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredDo NOT Day Trade (Do THIS instead)Forget day trading (especially in markets like these). Trade OVERNIGHT instead! I've uncovered a shockin...Monument Traders Alliance | SponsoredCollege grad makes $64,000 a monthIt's easy to feel like you've missed out on the biggest stock market boom of the century. But if you want t...Stansberry Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredAlert: Prepare for Trump's Dollar OverhaulPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Synaptogenix, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Synaptogenix With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free SNPX Stock Alerts